Alendronate
Treatment for Osteoporosis
Typical Dosage: 70 mg orally once weekly or 10 mg orally once daily
Effectiveness
60%
Safety Score
65%
Clinical Trials
154
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
70 mg orally once weekly or 10 mg orally once daily
Time to Effect
6-12 months
Treatment Duration
3-5 years (re-evaluation after)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
15(Treat 15 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1000(Treat 1000 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75
Monitoring:$250
Side Effect Mgmt:$50
Total Annual:$375
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$-5,000/QALY
QALYs Gained
0.15
Active Clinical Trials
1 active trial recruiting for Alendronate in Osteoporosis
Precision Medicine Approach for Osteoporosis - Follow Up Study
NCT06264609ENROLLING BY INVITATIONPHASE4
40 participants
INTERVENTIONAL
Lexington, United States
Started: Feb 1, 2024
Completed Clinical Trials
13 completed trials for Alendronate in Osteoporosis
Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis
NCT00936260COMPLETEDNA
228 participants
INTERVENTIONAL
Madrid, Spain
Started: Jan 1, 1998
Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis
NCT00259857COMPLETEDPHASE2
22 participants
INTERVENTIONAL
Charleston, United States
Started: Oct 1, 2003
FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)
NCT01065779COMPLETED
880 participants
OBSERVATIONAL
Started: Mar 1, 2006
Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis
NCT00010439COMPLETEDPHASE2
10 participants
INTERVENTIONAL
Charleston, United States
Started: Sep 1, 2000
The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss
NCT00460057COMPLETEDPHASE4
63 participants
INTERVENTIONAL
Started: Mar 1, 2006
Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis
NCT01657162COMPLETEDPHASE3
1.14K participants
INTERVENTIONAL
Lakewood, United States +24 more
Started: Nov 20, 2012
Treatment of Childhood Osteoporosis With Alendronate (Fosamax)
NCT00001720COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Bethesda, United States
Started: Mar 1, 1998
Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment
NCT02371252COMPLETEDPHASE4
140 participants
INTERVENTIONAL
Bangkok Noi, Thailand
Started: Apr 1, 2014
Denosumab Versus Bisphosphonates (Alendronate) in GIOP
NCT03005678COMPLETEDPHASE4
140 participants
INTERVENTIONAL
Hong Kong, China
Started: Apr 1, 2017
Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation
NCT04338529COMPLETED
92 participants
OBSERVATIONAL
Athens, Greece
Started: Apr 1, 2020
Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study
NCT02139007COMPLETEDPHASE4
27 participants
INTERVENTIONAL
Birmingham, United States
Started: Jun 1, 2014
PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis
NCT00005005COMPLETEDPHASE2
238 participants
INTERVENTIONAL
Bangor, United States +3 more
Started: Oct 1, 1999
Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate
NCT03051620COMPLETED
142 participants
OBSERVATIONAL
Aarhus, Denmark
Started: Feb 1, 2017
Showing 20 of 155 total trials